socalTECH

JUNE 11, 2021

The company begins trading this morning on the Nasdaq Global market under the ticker symbol JANX. Janux Therapeutics is developing T cell engager immunotherapies. The company's biggest shareholders before the IPO were Avalon Ventures, RA Capital Healthcare, Orbimed, Bregua Corporation, and Correlation Ventures.

Pricing 113

Pricing Avalon Capital Marketing 113

socalTECH

JANUARY 26, 2017

San Diego-based AnaptysBio , which develops antibodies for treating inflammation, has raised $75.0M AnaptysBio is backed by Frazier Healthcare, Novo A/S, Avalon Ventures, Alloy Ventures, Biotechnology Value Fund, HBM Healthcare Investments, and others. The company now trades as ANAB on the NASDAQ Global Select Market.

Avalon 113

Avalon San Diego Pricing Invest 113

socalTECH

JANUARY 17, 2017

San Diego-based AnaptysBio , which develops antibodies for treating inflammation, has set its estimated IPO pricing range, saying on Tuesday that it expects to price its IPO at between $14.00 The company is selling 4,000,000 shares of its common stock on the NASDAQ Global Select Market as ANAB. and $16.00

Pricing 113

Pricing Avalon Southern California Venice 113

socalTECH

NOVEMBER 25, 2008

San Diego-based Awarepoint, a developer of systems for tracking assets and patients in hospitals, has raised $13.3M The firm said the round was led by Cardinal partners, and also included Venrock and prior investor Avalon Ventures. in a Series D funding. The firm offers its services as software-as-a-service to the healthcare industry.

Avalon 100

Avalon San Diego Funding Services 100

Xconomy

JANUARY 26, 2017

biotech company to go public this year, raising $75 million in an IPO intended to finance development of antibody-based drugs for inflammatory disorders. As has been the case for biotechs over the past year , insiders helped Anaptys get to the public market. AnaptysBio is the first U.S. Stockholders who had invested in the.

Marketing 82

Marketing San Diego Invest Help 82

socalTECH

SEPTEMBER 19, 2008

We seem to receive lots of pitches from companies looking to attack the mobile market with their mobile software applications, but few who have deployed on-deck with carriers. in funding from Venrock, Avalon, and Masthead. Derrick Oien: We have a platform we develop, called ANTHEM. Intercasting is backed by $17.5M

Social Network 113

Social Network Anthem Mobile Java 113

Tech Zulu Event

DECEMBER 6, 2013

Auto-interfaces are clunky, and when a lot of these big tech companies IPO’d, a lot of them developed products that were endemic to the car industry – navigation, social graphs, etc. ” CHANGING THE FACE OF AUTOMOTIVE MARKETING. As they became adopted by millions, they leap-frogged us in terms of capability. .

Advertising 97

Advertising Startup Marketing Mobile 97

Xconomy

SEPTEMBER 30, 2016

Who will be first to market with a new type of cancer treatment known as CAR-T? Who will break free of the pack of companies developing drugs meant to prevent migraines? —Sarepta inked a research pact with Catabasis Pharmaceuticals (NASDAQ: CATB ) to develop a combination therapy for Duchenne.

Avalon 40

Avalon Thousand Oaks Study Startup 40